Evidence map›Paper›PMID 32474901›Full record

ArticleJournal of molecular neuroscience : MN2020

Selected LDLR and APOE Polymorphisms Affect Cognitive and Functional Response to Lipophilic Statins in Alzheimer's Disease.

Fabricio Ferreira de Oliveira, Elizabeth Suchi Chen, Marilia Cardoso Smith, Paulo Henrique Ferreira Bertolucci

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular neuroscience : MN, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 2 pooled it
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Observational
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Effect of liver X receptor agonist TO901317 on cognitive function in APP/PS1 double transgenic mice with AlzheimerZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2022
    Article
  12. Article
  13. Review
  14. Frontiers in dementia · 2022
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Fabricio Ferreira de OliveiraDepartment of Neurology and Neurosurgery, Escola Paulista de Medicina, Federal University of São Paulo (UNIFESP), Sao Paulo, SP, Brazil. fabricioferreiradeoliveira@hotmail.com.ORCID https://orcid.org/0000-0002-8311-0859
Elizabeth Suchi ChenDepartment of Morphology and Genetics, Escola Paulista de Medicina, Federal University of São Paulo (UNIFESP), Sao Paulo, SP, Brazil.ORCID https://orcid.org/0000-0002-3573-0164
Marilia Cardoso SmithDepartment of Morphology and Genetics, Escola Paulista de Medicina, Federal University of São Paulo (UNIFESP), Sao Paulo, SP, Brazil.ORCID https://orcid.org/0000-0002-1441-1033
Paulo Henrique Ferreira BertolucciDepartment of Neurology and Neurosurgery, Escola Paulista de Medicina, Federal University of São Paulo (UNIFESP), Sao Paulo, SP, Brazil.ORCID https://orcid.org/0000-0001-7902-7502
Universidade Federal de São Paulo · BR

Funding

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior 1067/10Fundação de Amparo à Pesquisa do Estado de São Paulo 2015/10109-5Fundação de Amparo à Pesquisa do Estado de São Paulo 2015/18125-0
6 · The paper itself

Abstract

Effects of statins over clinical changes in Alzheimer's disease (AD) are usually non-significant, but epistatic interactions between genetic variants involved in cholesterol metabolism could be important for such effects. We aimed to investigate whether LDLR single-nucleotide polymorphisms rs11669576 (LDLR8), rs5930 (LDLR10), and rs5925 (LDLR13) are associated with cognitive and functional changes in AD, while also considering APOE haplotypes and lipid-lowering treatment with lipophilic statins for stratification. Consecutive outpatients with late-onset AD were screened with cognitive tests, while caregivers scored functionality and caregiver burden, with prospective neurotranslational correlations documented for 1 year. For 179 patients, minor allele frequencies were 0.078 for rs11669576-A (14.5% heterozygotes), 0.346 for rs5930-A (42.5% heterozygotes), and 0.444 for rs5925-C (56.4% heterozygotes), all in Hardy-Weinberg equilibrium; 134 patients had hypercholesterolemia, and 133 used lipophilic statins. Carriers of rs11669576-G had faster cognitive decline, while functional decline was slower for carriers of rs11669576-A who used lipophilic statins. APOE-ε4 carriers who also carried rs5930-AA had improved caregiver burden, while carriers of haplotypes that included rs5930-AG had worse cognitive and functional outcomes, though carriers of the A allele of rs5930 had better cognitive and functional response to lipophilic statins. APOE-ε4 non-carriers who carried rs5925-TT had slower cognitive decline, while lipophilic statins protected carriers of the other genotypes. We preliminarily conclude that reportedly protective variants of LDLR and APOE against risk of AD also slowed cognitive decline, regardless of cholesterol variations, while therapy with lipophilic statins might benefit carriers of specific genetic variants.

Indexed as

CognitionPolymorphism, Single NucleotideAgedAged, 80 and overAlzheimer DiseaseApolipoproteins EEpistasis, GeneticFemaleHaplotypesHeterozygoteHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypercholesterolemiaMaleReceptors, LDLTreatment OutcomeApoE protein, humanApolipoproteins EHydroxymethylglutaryl-CoA Reductase InhibitorsLDLR protein, humanReceptors, LDLAlzheimer diseaseDementiaDrug therapyHydroxymethylglutaryl-CoA reductase inhibitorsNeuropsychiatryPharmacogenetics

Identifiers

PMID32474901
OpenAlexW3032173334

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.